Tags: Video tutorial autocad 2012Lhf chicago script video, Povratak otpisanih 1 epizoda skype , Video juubi vs kyubi mask, Red ball 2 game The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a new, self-administered, item questionnaire developed to provide a better description of HRQoL in patients with CHF. It quantifies, in a disease-specific fashion, physical limitation, symptoms (frequency, severity and recent change over time), QoL, social interference and mobilefocus.net by: The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a widely used heart failure specific HRQoL measure which has been translated and culturally adapted [4], . The Kansas City Cardiomyopathy Questionnaire Did the patient complete a KCCQ form? * YES NO How was the test administered?: * 1. Heart Failure affects different people in different ways. Graphical Tracking of Patient Outcomes With the KCCQ, SAQ, and PAQ Calculators. Monitoring serial changes in health status is one of the principal clinical uses of the ...

Background: Right heart failure (RHF) is an unresolved issue during continuous-flow left ventricular assist device (LVAD) support. There are scarce data about post-transplant outcomes in patients complicated with late RHF during LVAD support.. Objective: To assess whether development of late RHF during LVAD support adversely affected post-transplant survival.. Methods: Between May 2004 and December 2013, 141 patients underwent cardiac transplantation after isolated LVAD support as a bridge to transplant at our center. Late RHF was defined as HF requiring medical interventions ,4 weeks after LVAD implantation. During the same study period, 3 patients were bridged to transplant with concurrent right ventricular assist device (RVAD) support.. Results: The mean age of the study cohort was 54 ± 13 years, 81% were male, and 35% had an ischemic etiology. The mean duration of LVAD support before transplantation was 270 days. Twenty-three patients (16%) developed late RHF during waiting period. Of ...

TY - JOUR. T1 - Doxazosin for the treatment of chronic congestive heart failure. T2 - Results of a randomized double-blind and placebo-controlled study. AU - DiBianco, Robert. AU - Parker, John O.. AU - Chakko, Simon. AU - Tanser, Paul H.. AU - Emmanuel, George. AU - Singh, Jang B.. AU - Marlon, Anthony. PY - 1991/1/1. Y1 - 1991/1/1. N2 - In this study we evaluated the effects of once-daily administration of oral doxazosin in patients with chronic congestive heart failure (CHF). After a stabilization period of at least 2 weeks with digitalis and diuretics, 73 patients with chronic CHF were randomized to receive additionally either doxazosin or placebo in double-blind fashion. Patients underwent weekly dose adjustments with increasing doses of doxazosin (1, 2, 4, 8, and 16 mg daily) or placebo for 5 weeks, and 67 were evaluated for 12 additional weeks on maximally tolerated doses of blinded study drugs. Treatment groups were evaluated with respect to symptoms of heart failure, indexes of quality ...

TY - JOUR. T1 - Heart transplantation versus continuous-flow left ventricular assist device. T2 - Comprehensive cost at 1 year. AU - Patel, Snehal R.. AU - Sileo, Alan. AU - Bello, Ricardo. AU - Gunda, Sampath. AU - Nguyen, Jenni. AU - Goldstein, Daniel. PY - 2015/2/1. Y1 - 2015/2/1. N2 - Background With health care reform firmly on the horizon, it is critical to understand the costs associated with new technologies such as continuous-flow left ventricular assist device (CF-LVAD) compared with well established treatments such as heart transplantation (HT). Scarce data exist describing the costs of these 2 therapies after 1 year of support. Methods and Results The study population consisted of 20 consecutive subjects who underwent implantation of a CF-LVAD and 20 consecutive subjects who underwent HT and survived ≥1 year. Comprehensive cost calculation included all direct and indirect costs from day of operation through 365 days and were inflation adjusted to 2010 US dollars. Hospital charges ...

TY - JOUR. T1 - Watchful waiting in continuous-flow left ventricular assist device patients with ongoing hemolysis is associated with an increased risk for cerebrovascular accident or death. AU - Levin, Allison P.. AU - Saeed, Omar. AU - Willey, Joshua Z.. AU - Levin, Charles J.. AU - Fried, Justin A.. AU - Patel, Snehal R.. AU - Sims, Daniel B.. AU - Nguyen, Jenni D.. AU - Shin, Julia J.. AU - Topkara, Veli K.. AU - Colombo, Paolo C.. AU - Goldstein, Daniel J.. AU - Naka, Yoshifumi. AU - Takayama, Hiroo. AU - Uriel, Nir. AU - Jorde, Ulrich P.. PY - 2016/5/1. Y1 - 2016/5/1. N2 - Background - Management of hemolysis in the setting of suspected device thrombosis in continuous-flow left ventricular assist device patients varies widely, ranging from watchful waiting with intensified antithrombotic therapy to early surgical device exchange. The aim of this study was to compare the outcomes of hemolysis events treated with surgical interventions versus medical management alone. Methods and Results - A ...

TY - JOUR. T1 - Congestive Heart Failure Due to Giant Cutaneous Cavernous Hemangioma. AU - Howell, David M.. AU - Gumbiner, Carl H.. AU - Martin, Gladys E.O.. PY - 1984/9. Y1 - 1984/9. N2 - A female infant is presented with isolated giant cutaneous cavernous hemangioma with secondary severe congestive heart failure. Studies to identify other major arteriovenous malformations were negative. An attempt to treat the patient with a corticosteroid was not successful in reducing the size of the hemangioma. She required an aggressive anticongestive medical regimen for 2 years. Though not previously described, high output congestive heart failure can occur secondary to isolated cutaneous hemangioma. Aggressive medical management may alleviate the need for the increased risk of surgical or other therapeutic approaches in this often self-limited condition.. AB - A female infant is presented with isolated giant cutaneous cavernous hemangioma with secondary severe congestive heart failure. Studies to ...

BACKGROUND New generation continuous-flow left ventricular assist devices (LVADs) utilise centrifugal pumps. Data concerning their effect on patient haemodynamics, ventricular function and tissue perfusion is limited. We aimed to document these parameters following HeartWare centrifugal continuous-flow LVAD (HVAD) implantation and to assess the impact of post-operative right heart failure (RHF). METHODS We reviewed 53 consecutive patients (mean age 49.5 ± 14.1 yrs) with HVAD implanted in the left ventricle, at St. Vincents Hospital, Sydney, between January 2007 and August 2012. Available paired right heart catheterisation (n=35) and echocardiography (n=39) data was reviewed to assess response of invasive haemodynamics and ventricular function to LVAD support. RESULTS A total of 28 patients (53%) were implanted from interim mechanical circulatory support. Seventeen patients (32%) required short-term post-implant veno-pulmonary artery extracorporeal membrane oxygenation. At 100 ± 61 days ...

TY - JOUR. T1 - Effect of oral milrinone on mortality in severe chronic heart failure. AU - Packer, Milton. AU - Carver, Joseph R.. AU - Rodeheffer, Richard J.. AU - Ivanhoe, Russell J.. AU - DiBianco, Robert. AU - Zeldis, Steven M.. AU - Hendrix, Grady H.. AU - Bommer, William J.. AU - Elkayam, Uri. AU - Kukin, Marrick L.. AU - Mallis, George I.. AU - Sollano, Josephine A.. AU - Shannon, James. AU - Tandon, P. K.. AU - DeMets, David L.. PY - 1991/11/21. Y1 - 1991/11/21. N2 - Background. Milrinone, a phosphodiesterase inhibitor, enhances cardiac contractility by increasing intracellular levels of cyclic AMP, but the long-term effect of this type of positive inotropic agent on the survival of patients with chronic heart failure has not been determined. Methods. We randomly assigned 1088 patients with severe chronic heart failure (New York Heart Association class III or IV) and advanced left ventricular dysfunction to double-blind treatment with 40 mg of oral milrinone daily (561 patients) or ...

Pathophysiology of heart failure has been considered to be a damaged state of systolic function of the heart followed by a state of low cardiac output that is, systolic heart failure. Even if systolic function is preserved, left ventricular filling in diastole can be impeded and resulted in elevation of filling pressure and symptoms of heart failure. This kind of heart failure is called diastolic heart failure. Nowadays, diastolic heart failure is referred to as heart failure with preserved ejection fraction (HFpEF), whereas systolic heart failure is referred to as heart failure with reduced ejection fraction (HFrEF). In this paper, the similarities and differences between the pathogenesis and pathophysiology of diastolic and systolic heart failure were reviewed. Although diastolic heart failure is a common condition of heart failure worldwide, its pathophysiology has not been sufficiently elucidated. This is thought to be the most significant reason for a lack of established treatment methods for

Clinical trial for Chronic Systolic Heart Failure , Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets FIRST

Introduction: Stenosis in the continuous-flow left ventricular assist device (CF-LVAD) outflow graft can be caused by various mechanical and anatomical factors. Increasingly, percutaneous management has been utilized to re-establish adequate CF-LVAD flow. We sought to evaluate indications for such interventions and their outcomes. Methods: An electronic search was performed to identify all studies in the English literature reporting CF-LVAD outflow graft stenting for various etiologies. Twenty-one studies consisting of 26 patients were included in the analysis. Results: Median patient age was 59 years [45.8-67.0] and 65.4% (17/26) were male. 58.3% (14/24) of patients had HeartWare HVAD, 37.5% (9/24) had HeartMate II LVAD, and 4.2% (1/24) had HeartMate III LVAS. Median time from device placement to outflow graft stenting was 24.0 months [7.8-30.4]. 76.9% of patients (20/26) presented with heart failure. 34.6% (9/26) had outflow graft thrombosis, 34.6% (9/26) stenosis, 11.5% (3/26) kinking, 11.5% (3/26)

Article, see p 1772. Early randomized clinical trials of primary prevention implantable cardioverter defibrillators (ICDs) in patients with nonischemic cardiomyopathy failed to establish survival benefit from this therapy; however, those trials were too small to provide definitive results.1,2 When the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) was published in 2005, it was practice changing. SCD-HeFT showed that primary prevention ICDs significantly improve the survival of patients with a left ventricular ejection fraction ≤35% attributable to ischemic or nonischemic cardiomyopathy and New York Heart Association class II or III heart failure symptoms despite optimal medical therapy.3 Patients with nonischemic cardiomyopathy constituted about half of the 2521 total enrolled patients in SCD-HeFT.3 The results of SCD-HeFT formed the basis of a class I guideline recommendation for primary prevention ICDs in patients with New York Heart Association class II or III heart failure symptoms ...

Standard dual chamber pacing was first used as adjunctive treatment for severe congestive heart failure in the early 1990s.1 It was proposed that a short atrioventricular delay reduced presystolic mitral regurgitation.2,3 It also may correct chronotropic incompetence and protect against fatal bradyarrhythmias.. We performed a randomised study to test whether DDDR pacing with optimised atrioventricular (AV) delay and reversal of drug induced bradycardia by rate responsive pacing was beneficial in heart failure patients who were receiving combined treatment with amiodarone and β blockers as empirical prophylaxis against sudden tachyarrhythmic death.4. In 82 patients with severe heart failure submitted for heart transplantation and without a conventional pacemaker indication between 1996 and 1998 (85% male; 52% idiopathic dilated cardiomyopathy), treatment with low dose amiodarone (1000 mg/week) plus titrated doses of carvedilol (target 50 mg/day) was instituted. In addition, a dual chamber ...

malignant hypertensive heart disease with heart failure, malignant hypertensive heart disease with heart failure icd 10, malignant hypertensive heart disease without heart failure, malignant hypertensive heart disease without heart failure icd 10, malignant hypertensive heart disease without congestive heart failure, malignant hypertension with hypertensive heart disease and congestive heart failure

Heart failure-related hospitalizations increased between 1979 and 2004. This increase was consistent with other earlier reports of national hospitalization data (1-4,11-13); however, our report provides the most recent data. This increase was greater for hospitalizations among patients with heart failure as an additional diagnosis than among those with heart failure as the first-listed diagnosis. Moreover, among hospitalizations with any mention of heart failure, the proportion with a first-listed diagnosis of CHD and other CVD declined. However, the proportions of hospitalizations with first-listed diagnoses of respiratory or other non-CVD increased and surpassed CHD as the most common first-listed diagnosis. During the same period, in-hospital mortality declined among patients hospitalized with heart failure. This decline was greater among hospitalizations with heart failure as the first-listed diagnosis than among those with an additional diagnosis of heart failure.. The growing burden of ...

TY - JOUR. T1 - The Influence of Rheumatoid Arthritis Disease Characteristics on Heart Failure. AU - Myasoedova, Elena. AU - Crowson, Cynthia S.. AU - Nicola, Paulo J.. AU - Maradit-Kremers, Hilal. AU - Davis, John M.. AU - Roger, Véronique L.. AU - Therneau, Terry M.. AU - Gabriel, Sherine E.. N1 - Copyright: Copyright 2012 Elsevier B.V., All rights reserved.. PY - 2011/8. Y1 - 2011/8. N2 - Objective. To examine the influence of rheumatoid arthritis (RA) characteristics and antirheumatic medications on the risk of heart failure (HF) in patients with RA. Methods. A population-based incidence cohort of RA patients aged ≥ 18 years (1987 American College of Rheumatology criteria first met between January 1, 1980, and January 1, 2008) with no history of HF was followed until onset of HF (defined by Framingham criteria), death, or January 1, 2008. We collected data on RA characteristics, antirheumatic medications, and cardiovascular (CV) risk factors. Cox models adjusting for age, sex, and ...

MUSC Division of Cardiology presents the Charleston HFpEF Conference: The Latest Knowledge on Heart Failure with preserved Ejection Fraction and will be held from Apr 17 - 19, 2020 at Charleston, South Carolina, USA. Approved for CME. ...

TY - JOUR. T1 - Short-term hemodynamic effects of cardiac resynchronization therapy in patients with heart failure, a narrow QRS duration, and no dyssynchrony.. AU - Williams, LK. AU - Ellery, S. AU - Patel, K. AU - Leyva, F. AU - Bleasdale, RA. AU - Phan, TT. AU - Stegemann, B. AU - Paul, V. AU - Steendijk, P. AU - Frenneaux, M. PY - 2009/10/12. Y1 - 2009/10/12. N2 - Background- Cardiac resynchronization therapy produces both short-term hemodynamic and long-term symptomatic/mortality benefits in symptomatic heart failure patients with a QRS duration ,120 ms. This is conventionally believed to be due principally to relief of dyssynchrony, although we recently showed that relief of external constraint to left ventricular filling may also play a role. In this study, we evaluated the short-term hemodynamic effects in symptomatic patients with a QRS duration ,120 ms and no evidence of dyssynchrony on conventional criteria and assessed the effects on contractility and external constraint. Methods and ...

TY - JOUR. T1 - Percutaneous Axillary Intra-aortic Balloon Pump Insertion Technique as Bridge to Advanced Heart Failure Therapy. AU - Rosenbaum, Andrew N.. AU - Jain, C. Charles. AU - Shadrin, Ilya Y.. AU - El Hajj, Stephanie C.. AU - El Sabbagh, Abdallah. AU - Behfar, Atta. N1 - Publisher Copyright: © 2021 Lippincott Williams and Wilkins. All rights reserved.. PY - 2021. Y1 - 2021. N2 - In patients with advanced heart failure (HF), temporary mechanical circulator support (TMCS) is used to improve hemodynamics, via left ventricular unloading, and end-organ function as a bridge to definitive therapy. While listed for cardiac transplantation, use of TMCS may be prolonged, preventing adequate mobility. Here, we describe the technique for placement of a percutaneous axillary intra-aortic balloon pump (IABP) using single-site arterial access to facilitate ambulation and subsequent safe removal without surgery or a closure device. Retrospective review of the experience with this approach at a single ...

Administration of IV furosemide to patients with ADHF typically results in a prompt diuretic effect (within 30 minutes) that peaks at 1.5 hours. This effect leads to a decrease in ventricular filling pressures and improvement in symptoms in the majority of patients with ADHF. This observation has been confirmed in the placebo groups of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies and the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan, in which treatment based primarily on loop diuretics was associated with rapid and substantial improvement of dyspnea.29,30. Despite this clinical efficacy, substantial questions remain about how to best use diuretics to treat volume overload in patients with heart failure. One major unanswered issue is the most appropriate dosing strategy for loop diuretics in ADHF. There are almost no data evaluating the relationship between diuretic dose and diuretic efficacy in ADHF. In the ...

TY - JOUR. T1 - Characteristics and outcomes in African American patients with decompensated heart failure. AU - Kamath, Sandeep A.. AU - Drazner, Mark H.. AU - Wynne, Janet. AU - Fonarow, Gregg C.. AU - Yancy, Clyde W.. N1 - Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2008/6/9. Y1 - 2008/6/9. N2 - Background: Outcomes in patients with chronic heart failure vary by race. Racial differences in the characteristics and outcomes of patients with acute decompensated heart failure (ADHF) have not been well characterized. Therefore, we assessed race-related differences in presentation, treatment, in-patient experiences, and short-term mortality due to ADHF before and after accounting for known covariates. Methods: The Acute Decompensated Heart Failure National Registry database was analyzed to evaluate demographic and mortality differences in African American and white patients with ADHF entered into the database from its initiation in September 2001 to December 31, 2004. ...

The lifestyle modification program participants consumed a very low-energy diet of 500 calories a day for 3 to 10 weeks followed by 2 to 8 weeks of gradual incorporation of food, and then 9 months of a weight-maintenance regimen that included regular exercise, dietary advice and behavioral therapy. Around 20 percent of patients in the lifestyle modification program dropped out by the first year.. Our study shows an association between obesity and heart failure and offers support for efforts to prevent and treat obesity aggressively, including the use of bariatric surgery, said Johan Sundstrom, M.D., Ph.D., senior author of the study and professor of epidemiology at Uppsala University in Sweden. Bariatric surgery might affect the incidence of atrial fibrillation, diabetes and hypertension - known risk factors of heart failure - explaining the lower risk of heart failure we observed.. While the findings report that heart failure risk is lower in patients who lose more weight, it does not prove ...

TY - JOUR. T1 - Comparative Efficacy of Cardiac Resynchronization Therapy in Africans Americans Compared with European Americans. AU - Rickard, John. AU - Baranowski, Bryan. AU - Cheng, Alan. AU - Spragg, David. AU - Tedford, Ryan. AU - Mukherjee, Monica. AU - Tang, W. H.Wilson. AU - Wilkoff, Bruce L.. AU - Varma, Niraj. PY - 2015/10/1. Y1 - 2015/10/1. N2 - Race has seldomly been reported in the major clinical trials of cardiac resynchronization therapy (CRT). When described, African Americans (AAs) were substantially under-represented. This study sought to compare reverse ventricular remodeling and long-term outcomes in AAs versus European Americans (EAs) with advanced heart failure who underwent CRT. We extracted demographic (including race), clinical, and echocardiographic data on patients with advanced heart failure who underwent CRT with a left ventricular ejection fraction (LVEF) ≤35% and a QRS duration ≥120 ms. Long-term outcomes were compared between AAs and EAs. In patients in whom ...

DESCRIPTION: Congestive heart failure in the presence of normal or near normal left ventricular systolic function is referred to as diastolic heart failure. According to the applicant, it is thought that at least 50% of patients older than 65 years hospitalized with heart failure in 1995 (over 350,000 patients), had primary diastolic heart failure. Rates of re-hospitalization and costs associated with diastolic heart failure are equivalent to those of systolic heart failure, although mortality is lower. Despite its prevalence, the physiology of diastolic failure is poorly understood, the optimal diagnostic strategy has yet to be defined, and no therapy has been shown to lower the mortality of the disease. The research phase of this proposal, which is in four parts, will examine the roles of volume status, arterial stiffness, and myocardial relaxation in the pathophysiology of diastolic dysfunction in an elderly population. In Part 1, the effects of lowering intracardiac filling pressures on ...

TY - JOUR. T1 - Symptom status and quality-of-life outcomes of home-based disease management program for heart failure patients.. AU - Todero, Catherine. AU - LaFramboise, Louise M.. AU - Zimmerman, Lani M.. PY - 2002. Y1 - 2002. N2 - Symptom occurrence, symptom characteristics (frequency, severity, interference with activities and enjoyment of life), and quality of life were examined in heart failure patients after release from the hospital and 2 months after enrollment in a home-based disease management program. The results provide information on the most common and distressing symptoms in a community-based heart failure population. This information may be useful in guiding assessments and designing specific nursing interventions to include in a home-based disease management program.. AB - Symptom occurrence, symptom characteristics (frequency, severity, interference with activities and enjoyment of life), and quality of life were examined in heart failure patients after release from the ...

TY - JOUR. T1 - Percutaneous occlusion of patent ductus arteriosus for an elderly patient with refractory congestive heart failure. AU - Shoji, Satoshi. AU - Kanazawa, Hideaki. AU - Yanagisawa, Ryo. AU - Tanaka, Makoto. AU - Fukuoka, Ryoma. AU - Akita, Keitaro. AU - Kimura, Mai. AU - Arai, Takahide. AU - Kawakami, Takashi. AU - Hayashida, Kentaro. AU - Yuasa, Shinsuke. AU - Tsuruta, Hikaru. AU - Itabashi, Yuji. AU - Murata, Mitsushige. AU - Nishiyama, Takahiko. AU - Kohno, Takashi. AU - Maekawa, Yuichiro. AU - Fukuda, Keiichi. PY - 2018/2/1. Y1 - 2018/2/1. UR - http://www.scopus.com/inward/record.url?scp=85052330940&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85052330940&partnerID=8YFLogxK. U2 - 10.1161/CIRCHEARTFAILURE.117.004764. DO - 10.1161/CIRCHEARTFAILURE.117.004764. M3 - Short survey. C2 - 29367269. AN - SCOPUS:85052330940. VL - 11. JO - Circulation: Heart Failure. JF - Circulation: Heart Failure. SN - 1941-3297. IS - 2. M1 - e004000. ER - ...

By working with an agent who specializes in this type of life insurance, you will increase your chances of finding the most affordable coverage. With todays high medical cost, any money saved will help in reducing your over all monthly expenses in managing your Congestive Heart Failure medical condition. In fact, the longer you are in good health, the greater your chances are of qualifying for a more affordable whole life insurance policy. Even If your health condition with Congestive Heart Failure is deteriorating and you are concerned that you will not qualify life insurance, you can still get coverage. Congestive Heart Failure treatment can be successful if the condition is detected early and proper treatment started early. As with some of our policies you will not have any health questions or medical exam to qualify for coverage. There are also things you can do to help getting affordable coverage, like doing your best to stay healthy and avoid smoking. You can always get coverage with a ...

The purpose of this study was to assess the hemodynamic effects of intravenous digoxin in patients with New York Heart Association class IV heart failure, who had never previously been treated with digitalis drugs, and who were initially treated only with diuretics and systemic vasodilators to clinical end points of compensation. Eleven male patients, S with idiopathic and 6 with ischemic cardiomyopathy, had sinus rhythm and were hospitalized with congestive heart failure not precipitated by an acute ischemic event. All 11 patients were treated with intravenous furosemide and various vasodilators without invasive hemodynamic monitoring for a mean period of 4.3 ± 2.1 days. This therapy resulted in subjective and objective improvement in all patients as reflected by a significant decrease in heart failure score from 9.5 ± 2.2 to 2.7 ± 2.3 (p , 0.001).. When compensation was achieved by clinical criteria, the patients were instrumented and hemodynamics obtained before and serially thereafter for ...

WhiteSwell Strengthens Patent Portfolio for Treatment of Acute Decompensated Heart Failure with Newly Issued U.S. Patent. Adds to Portfolio of 40 Patents for Catheter-Based Technology That Leverages Power of Bodys Natural Fluid Removal Process. GALWAY, Ireland - December 16, 2020 - WhiteSwell, a company pioneering new ways to treat acute decompensated heart failure, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the company a new patent for treating ADHF patients with a catheter technology designed to stimulate lymphatic drainage using a novel impeller pump combined with restrictors.. This patent grant, which is WhiteSwells third this year, adds to its rapidly expanding U.S. patent portfolio covering a set of devices that leverage the lymphatic systems remarkable innate drainage properties for fluid-overloaded ADHF patients. WhiteSwell has received 10 patent grants from the U.S. PTO in the last two years, and has a U.S. portfolio of over 40 patents granted or ...

Registered Charity Number 1151848. Systolic congestive heart failure makes it difficult for the heart to pump blood through the body, meaning that other organs get less blood than they need. NLM Congestive heart failure (CHF) is a chronic heart condition that affects how the heart pumps blood. There are a lot of interesting things you can do with breathing, said Dr. Uber, Physicians can teach patients how to synchronize their breath properly and this requires little practice for 15 minutes a day. Copyright © 2014 Elsevier Inc. All rights reserved. Effect of cardiac resynchronization therapy on sleep quality, quality of life, and symptomatic depression in patients with chronic heart failure and Cheyne-Stokes respiration. Your vet may prescribe additional diuretics like furosemide. BPAP; CPAP; Central sleep apnea; Cheyne-Stokes respiration; Heart failure; Obstructive sleep apnea; Sleep apnea; Sleep-disordered breathing. Pumping Marvellous Foundation, Suite 111 Business First, Millennium City ...

Umme Habiba Ferdaushi abstract presented on Short term outcome of cardiac resynchronization therapy on functional recovery of patients with congestive heart failure in Bangladeshi population at Euro Heart Failure 2017 | Conferenceseries Ltd

Mechanistic studies of human heart failure are complicated by the prolonged time course of development of the disease, the technical challenges of isolating cardiac tissue or cells from explanted hearts, the inability to investigate the early time course of cellular alterations, and the lack of control over experimental conditions. Thus, it is fortunate that the canine tachycardia-induced heart failure model so closely reproduces the known hemodynamic and ionic changes that have been identified in human hearts. The present findings indicate that, in addition to the electrophysiological changes noted in earlier studies, significant alterations in Ca2+ handling occur in isolated myocytes from failing hearts, following the general pattern of human studies. Through biochemical and functional measurements in the same hearts, we have found strong evidence in support of the hypothesis that the induction of heart failure triggers a shift in the balance of cytosolic Ca2+ extrusion mechanisms from SR Ca2+ ...

Weight is one way to identify if heart failure is getting worse or if changes to medication are required to control extra fluid.. A new mobile app which has been developed in collaboration between the Irish Heart Foundation, Team OSVX, and PerCen Technologies, is a self-care tool that removes the need for written weight logs and ensures the patient is alerted when their weight increases by more than two kilograms in a seven-day period, which can be a sign of worsening heart failure.. The Fluid Heart Tracker app was developed in response to a patient need, identified by Clinical Nurse Specialist in Heart Failure, Norma Caples, and community heart failure nurse specialists around the country. Community heart failure nurses were concerned that their patients were hesitant to attend their GP or hospital with heart failure-related symptoms due to the risks of COVID-19. Norma first proposed this app to the Health Innovation Hub Ireland Spark Ignite 2020 and now, following significant user testing, it ...

In our cross-sectional cohort, iron deficiency was the most common cause of anemia. Notably, 49% of the iron-deficient patients were already on iron supplementation. In our retrospective cohort, 59% of the patients were anemic after 6 months of support. Anemic patients were older, had lower albumin, higher brain natriuretic peptide (BNP), worse renal function and New York Heart Association (NYHA) class. Anemia had a HR of 3.16 (95%CI 1.38-7.26) to predict a composite of 1-year death and HF readmissions, as well as HF-readmissions alone.. ...

Methods and Results-In 86 stable patients with HF and EF ≥45% in the Karolinska Rennes (KaRen) biomarker substudy, biomarkers were quantified by a multiplex immunoassay. Orthogonal projection to latent structures by partial least square analysis was performed on 87 biomarkers and 240 clinical variables, ranking biomarkers associated with New York Heart Association (NYHA) Functional class and the composite outcome (all-cause mortality and HF hospitalization). Biomarkers significantly correlated with outcome were analyzed by multivariable Cox regression and correlations with echocardiographic measurements performed. The orthogonal partial least square outcome-predicting biomarker pattern was run against the Ingenuity Pathway Analysis (IPA) database, containing annotated data from the public domain. The orthogonal partial least square analyses identified 32 biomarkers correlated with NYHA class and 28 predicting outcomes. Among outcome-predicting biomarkers, growth/differentiation factor-15 was ...

Data Shown at Heart Failure Society of America Meeting. Minneapolis and Toronto - Sept. 22, 2008 - Clinical data on the use of the CVRx® Rheos® System in treating early-stage heart failure patients shows Rheos Therapy significantly improved heart structure and function. John D. Bisognano, M.D, Ph.D., associate professor of medicine at the University of Rochester School of Medicine and Dentistry, New York, presented the data in a Sept. 22 poster session at the Heart Failure Society of America (HFSA) 12th Annual Scientific Meeting inToronto. In heart failure patients, the heart becomes enlarged and functions inefficiently, increasing the risk of death and poor qualify of life. Reducing heart size lowers these risks.. With one year of Rheos Therapy, the improvements in cardiac structure and function were significant in heart failure patients, and have not been seen with aggressive medical therapy currently available, said Nadim Yared, CVRx president and chief executive officer. We are excited ...

Borlaug, BA, Paulus, WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur. vol. 32. Heart J 2011. pp. 670. Aurigemma, GP, Gaasch, WH. Clinical practice. Diastolic heart failure. N Engl J Med. vol. 351. 2004. pp. 1097. Owan, TE, Hodge, DO, Herges, RM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. vol. 355. 2006. pp. 251(This longitudinal investigation among persons hospitalized from decompensates of heart failure demonstrates the increasing incidence of HFpEF over time as as a predilection among community patients.). Masoudi, FA, Havranek, EP, Smith, G. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol. vol. 41. 2003. pp. 217(An investigation of cross-sectional design of 19,710 Medicare beneficiaries detected the presence of heart failure among 35%. Following adjustment for patient factors, older age and female gender were associated with the ...

Introduction: Patient participation is important for improving outcomes and respecting selfdetermination and legal aspects in care. Heart failure is a chronic condition that puts high demands on self-care and patient participation. Patients often need advanced care due to deterioration of their heart failure symptoms, and one option is to provide care as home-care. There is limited knowledge of how patients with heart failure and their partners view participation in home-care.. Aim: The overall aim of this thesis was to describe different perspectives of participation in structured heart failure home-care among patients with heart failure and their partners.. Methods: All patients in this thesis received structured heart failure home-care, according to a model aiming to facilitate care, where safety, participation, and gaining knowledge about the illness and treatment, are in focus. Study I had a prospective pre-post longitudinal design including 100 patients with heart failure receiving ...

This brief CME publication explores clinical evidence for the use of left ventricular assist devices (LVADs) in patients with advanced heart failure. It also reviews the evolution of LVADs from first-generation to third-generation devices and discusses therapeutic indications and contraindications for LVADs. Additionally, in a short introductory video, a faculty expert discusses approaches for identifying patients who may be candidates for LVADs and the evolving role of these devices in the treatment of advanced heart failure.

|i|Background|/i|. Inflammation is a critical process contributing to heart failure (HF). We hypothesized that IL-33/ST2 pathway, a new mechanism regulated during cardiac stress, may be involved in the functional worsening of end-stage HF patients, candidates for left ventricular assist device (LVAD) implantation, and potentially responsible for their outcome. |i|Methods|/i|. IL-33, ST2, and conventional cytokines (IL-6, IL-8, and TNF-|i|α|/i|) were determined in cardiac biopsies and plasma of 22 patients submitted to LVAD implantation (pre-LVAD) and compared with (1) control stable chronic HF patients on medical therapy at the moment of heart transplantation without prior circulatory support (HT); (2) patients supported by LVAD at the moment of LVAD weaning (post-LVAD). |i|Results|/i|. Cardiac expression of ST2/IL-33 and cytokines was lower in the pre-LVAD than in the HT group. LVAD determined an increase of inflammatory mediators comparable to levels of the HT group. Only ST2 correlated with

Aims: To evaluate the effects of digoxin in patients with the newly described phenotype of heart failure (HF) and mid-range ejection fraction (HFmrEF), attributed to mild left ventricular systolic dysfunction. Methods and results: We carried out a retrospective analysis of the Digitalis Investigation Group (DIG) trial which had 7788 patients available for analysis with a left ventricular ejection fraction (LVEF) ranging between 3% and 85%. We compared the effect of digoxin to placebo in three mutually exclusive groups of patients defined by LVEF category: ,40% (HF with reduced LVEF, HFrEF, n = 5874), 40-49% (HFmrEF, n = 1195) and ≥50% (HF with preserved LVEF, HFpEF, n = 719). The primary outcome was the composite of cardiovascular death or HF hospitalisation. Patients with HFmrEF resembled patients with HFrEF, more than those with HFpEF, with respect to age, sex and aetiology but were more like HFpEF patients with respect to blood pressure and the prevalence of hypertension. Event rates in ...

Abstract: Recent studies report surprisingly low rates of implantable cardioverter defibrillator (ICD) placement for primary prevention against sudden cardiac death among patients with heart failure and left ventricular systolic dysfunction. Reasons for the low rates of utilization are not well understood. The authors examined ICD implantation rates at a university-based tertiary care center and used multivariable analysis to identify independent factors associated with ICD utilization. The ICD implantation rate for 850 eligible patients was 70%. Forty-seven (18%) patients refused implantation; women were twice as likely to refuse compared to men (8% vs 4%, P=.013). Race was not associated with utilization. On multivariable analysis, independent predictors of implantation included having a heart failure specialist (odds ratio [OR], 8.13; P,.001) or general cardiologist (OR, 2.23; P=.13) managing care, age range 70 to 79 (OR, 0.55; P,.001) or 80 and older (OR, 0.26; P,.001), female sex (OR, 0.49; ...

Two 12-week, double-blind, placebo-controlled studies enrolled 178 (RADIANCE trial) and 88 (PROVED trial) adult patients with NYHA class II or III heart failure previously treated with oral digoxin, a diuretic, and an ACE inhibitor (RADIANCE only) and randomized them to placebo or treatment with LANOXIN Tablets. Both trials demonstrated better preservation of exercise capacity in patients randomized to LANOXIN. Continued treatment with LANOXIN reduced the risk of developing worsening heart failure, as evidenced by heart failure-related hospitalizations and emergency care and the need for concomitant heart failure therapy. The larger study also showed treatment-related benefits in NYHA class and patients global assessment. In the smaller trial, these trended in favor of a treatment benefit.. The Digitalis Investigation Group (DIG) main trial was a multicenter, randomized, double-blind, placebo-controlled mortality study of 6,801 adult patients with heart failure and left ventricular ejection ...

Anemia associated with chronic heart failure: current concepts Ravish Shah, Anil K AgarwalDivision of Nephrology, The Ohio State University, Columbus, Ohio, USAAbstract: Anemia is a frequent comorbidity of heart failure and is associated with poor outcomes. Anemia in heart failure is considered to develop due to a complex interaction of iron deficiency, kidney disease, and cytokine production, although micronutrient insufficiency and blood loss may contribute. Currently, treatment of anemia of heart failure lacks clear targets and specific therapy is not defined. Intravenous iron use has been shown to benefit anemic as well as nonanemic patients with heart failure. Treatment with erythropoietin-stimulating agents has been considered alone or in combination with iron, but robust evidence to dictate clear guidelines is not currently available. Available and emerging new agents in the treatment of anemia of heart failure will need to be tested in randomized, controlled studies.Keywords: anemia, heart

Objective: To evaluate the influence of chronic heart failure (CHF) on resting lung volumes in patients with COPD, i.e., inspiratory fraction-inspiratory capacity (IC)/TLC-and relative inspiratory reserve-[1 − (end-inspiratory lung volume/TLC)]. Methods: This was a prospective study involving 56 patients with COPD-24 (23 males/1 female) with COPD+CHF and 32 (28 males/4 females) with COPD only-who, after careful clinical stabilization, underwent spirometry (with forced and slow maneuvers) and whole-body plethysmography. Results: Although FEV1, as well as the FEV1/FVC and FEV1/slow vital capacity ratios, were higher in the COPD+CHF group than in the COPD group, all major static volumes-RV, functional residual capacity (FRC), and TLC-were lower in the former group (p , 0.05). There was a greater reduction in FRC than in RV, resulting in the expiratory reserve volume being lower in the COPD+CHF group than in the COPD group. There were relatively proportional reductions in FRC and TLC in the two ...

In recent decades, the prevalence of heart failure has steadily increased and can be considered a contemporary cardiovascular epidemic. Therefore, treatment of heart failure is a primary focus of cardiovascular disease management strategies. Cardiac resynchronization therapy: an established pacing therapy for heart failure and mechanical dyssynchrony provides basic knowledge about congestive heart failure and also covers the evolution of cardiac resynchronization therapy. State-of-the-art information and future directions of this therapeutic tool are explained. As cardiac resynchronization therapy (CRT) is a new therapy which still undergoes rapid advancement, it is imperative to provide updates on key issues. These include technological advances, the unique role of imaging to assess mechanical dyssynchrony, troubleshooting, recent key clinical trials, and the incorporation of monitoring capabilities into CRT or CRT plus defibrillation devices. Cardiac resynchronization therapy is an exciting ...

TY - JOUR. T1 - Duration of Left Ventricular Assist Device Support Does Not Impact Survival After US Heart Transplantation. AU - Grimm, Joshua C.. AU - Magruder, J. Trent. AU - Crawford, Todd C.. AU - Fraser, Charles D.. AU - Plum, William G.. AU - Sciortino, Christopher M.. AU - Higgins, Robert. AU - Whitman, Glenn. AU - Shah, Ashish S.. PY - 2016/10/1. Y1 - 2016/10/1. N2 - Background The aim of this study was to determine whether the duration of left ventricular device support (LVAD) influenced outcomes after orthotopic heart transplantation in a modern, bridge to transplant national cohort. Methods The United Network for Organ Sharing database, which has recently made pretransplant LVAD duration available, was queried for all adult bridge to transplant patients between January 2011 and December 2012. Three LVAD duration cohorts were generated, as follows: short (less than 90 days), intermediate (90 to 365 days), and prolonged (more than 365 days). Recipient, donor, and transplant-specific ...

TY - JOUR. T1 - Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. T2 - A double-blind, placebo-controlled, randomized crossover trial. AU - Marcus, Lee S.. AU - Hart, Douglas. AU - Packer, Milton. AU - Yushak, Madeline. AU - Medina, Norma. AU - Danziger, Robert S.. AU - Heitjan, Daniel F.. AU - Katz, Stuart D.. PY - 1996. Y1 - 1996. N2 - Background: The pharmacological effects of infusion of human brain natriuretic peptide (hBNP) in patients with severe congestive heart failure have not been characterized previously. Methods and Results: Twenty patients with severe congestive heart failure were randomized in a double-blind, placebo-controlled, crossover trial to receive incremental 90-minute infusions of hBMP (0.003, 0.01, 0.03, and 0.1 μg/kg per minute) or placebo on 2 consecutive days. At the highest completed dose of the hBNP, mean pulmonary artery pressure decreased from 38.3±1.6 to 25.9±1.7 mm Hg; mean pulmonary ...

Heart failure is a leading cause of cardiovascular mortality with limited options for treatment. We analyzed whether the anti-ischemic drug ranolazine could retard the progression of heart failure in an experimental model of heart failure induced by 6 months of chronic pressure overload. The study showed that 2 months of ranolazine treatment improved cardiac function of aortic constricted C57BL/6J (B6) mice with symptoms of heart failure as assessed by echocardiography. The microarray gene expression study of heart tissue from failing hearts relative to ranolazine-treated and healthy control hearts identified heart failure-specific genes that were normalized during treatment with the anti-ischemic drug ranolazine Show more ...

TY - JOUR. T1 - Plasma phospholipid fatty acid composition and estimated desaturase activity in heart failure patients with metabolic syndrome. AU - Lee, Seungmin. AU - Do, Hyun Ju. AU - Kang, Seok Min. AU - Chung, Ji Hyung. AU - Park, Eunju. AU - Shin, Min Jeong. PY - 2012/9. Y1 - 2012/9. N2 - Metabolic syndrome is one of the major factors to increase the incidence of heart failure. In our study, we compared plasma fatty acid compositions among heart failure patients with and without Metabolic syndrome. Fatty acid (FA) composition of plasma phospholipids was analyzed and the activities of desaturase were estimated as the ratio of substrate and product fatty acids in 85 stable heart failure patients. Fatty acid and estimated desaturase activities were further examined for their associations with Metabolic syndrome components. Heart failure patients with Metabolic syndrome showed significant changes in fatty acid composition in comparison to those without Metabolic syndrome, which had a decreased ...

TY - JOUR. T1 - Mechanical circulatory support in patients with heart failure secondary to transposition of the great arteries. AU - Joyce, David L.. AU - Crow, Sheri S.. AU - John, Ranjit. AU - St. Louis, James D.. AU - Braunlin, Elizabeth A.. AU - Pyles, Lee A.. AU - Kofflin, Paula. AU - Joyce, Lyle D.. N1 - Copyright: Copyright 2011 Elsevier B.V., All rights reserved.. PY - 2010/11. Y1 - 2010/11. N2 - Advances in palliation of congenital heart disease have resulted in improved survival to adulthood. Many of these patients ultimately develop end-stage heart failure requiring left ventricular assist device implantation (LVAD). However, morphologic differences in the systemic ventricle of these patients require careful attention to cannula placement. We report on the evolution of our surgical technique for implanting LVADs in 3 patients with transposition of the great arteries and congenitally corrected transposition of the great arteries. Applying standard LV cannulation techniques to the ...

Diastolic heart failure (also known as heart failure with normal ejection fraction or heart failure with preserved ejection fraction) occurs even though the heart muscles pumping function is normal. In many cases diastolic heart failure is related to stiffening of the heart and blood vessels in people who have high blood pressure. Current guidelines suggest that patients should limit the salt content of their diet, as too much salty food can cause fluid retention and other problems in diastolic heart failure. Studies in animals with diastolic heart failure suggest that antioxidant chemicals found in grapes can block some of the harmful effects of salty diets. Because it is often difficult for patients with diastolic heart failure to maintain a low salt diet, the investigators are researching the effects of the antioxidant properties of grape seed extract, a natural supplement made from grape seeds. The investigators hypothesize that supplementing the diet with grape seed extract (GSE) can ...

Readmissions after continuous flow left ventricular assist devices implantation are common. We compared the frequency and etiology of readmissions between two continuous flow left ventricular assist devices 6 months after implant. We retrospectively assessed readmissions in 81 patients who received a bridge to transplant HeartMate-II (HM-II) n = 35, 43% or HeartWare (HW) n = 46, 57%, from 2009 to ...

Background and aims: The effects of central sleep apnea in Cheyne-Stokes respiration on sleep-related symptoms and quality of life are not very well established. We aimed to investigate whether Cheyne-Stokes respiration is related to health-related quality of life. We also studied the impact on daytime sleepiness and nocturnal dyspnea.. Methods: Included were 203 consecutive patients, stabilized following in-hospital treatment for decompensated congestive heart failure. They underwent overnight cardiorespiratory sleep apnea recordings in hospital and answered a set of questions on symptoms and health-related quality of life questionnaires in the form of the Nottingham Health Profile and the Minnesota Living with Heart Failure Questionnaire. After excluding seven patients with predominantly obstructive apneas and 14 with insufficient recordings, 182 patients were included in the final analysis.. Results: One third of the patients had an apnea-hypopnea index (AHI) of ,30. Falling asleep in front ...

Introduction: Aortic valve stenosis imposes a pressure overload on the left ventricle. Congestive heart failure is one of the complications which can appear, even years after the operation. The main questions are: why do patients still develop heart failure? Which types of congestive heart failure can be expected? Which factors related to it are known? Methods: A literature search was performed with the terms aortic valve disease/replacement AND heart failure. Some secondary references derived from their reference list were also included. The study design of the selected papers differed considerably. Therefore, the analysis is descriptive and concerns factors which can be related to congestive heart failure. Furthermore, surrogate outcomes are ejection fraction, hypertrophy, long axis ventricular function, torsion, left atrial indices, pressures in the left sided heart and in the pulmonary circulation as well as a number of other echocardiographic parameters. Results: It has become clear that ...

Hunt, S. A., Abraham, W. T., Chin, M. H., et. al.: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005, 112, e154-e235.. Chin M. H. , ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for ...

Wireless Device Can Cut Heart Failure-Related Hospitalizations, Ohio State University Medical Center Study - read this article along with other careers information, tips and advice on BioSpace

TY - JOUR. T1 - Lo studio AREA IN-CHF (Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure). T2 - Razionale e disegno. AU - Cacciatore, Giuseppe. AU - Boccanelli, Alessandro. AU - Mureddu, Gian Francesco. AU - Maggioni, Aldo Pietro. AU - Latini, Roberto. AU - Masson, Serge. AU - De Simone, Giovanni. PY - 2005/1. Y1 - 2005/1. N2 - The RALES study has shown that spironolactone reduces the risk of morbidity and mortality both from progressive heart failure and sudden death in patients with NYHA class III or IV heart failure. This favorable effect was clearly independent of a diuretic effect. EPHESUS extended these results to eplerenone in patients with acute myocardial infarction complicated by left ventricular dysfunction and signs of heart failure. Antialdosterone drugs may be effective because they oppose the effects of aldosterone to sodium retention, loss of magnesium and potassium, sympathetic activation, baroreceptor function and vascular ...

There are a variety of conditions that can significantly increase the bodys need for blood and oxygen, resulting in high-output heart failure. These conditions include anemia, hyperthyroidism, and pregnancy. Although the causes of high-output heart failure are different from the cause of other types of heart failure, the end result is the same: Your heart isnt supplying enough blood to meet your bodys needs. High-output heart failure results in the same symptoms of heart failure, including fatigue and shortness of breath.. ...

TY - JOUR. T1 - Current Axial-Flow Devices-the HeartMate II and Jarvik 2000 Left Ventricular Assist Devices. AU - John, Ranjit. PY - 2008/9/1. Y1 - 2008/9/1. N2 - The increased applicability and excellent results with left ventricular assist devices (LVADs) have revolutionized the treatment options available for patients with end-stage heart failure. Until recently, most patients who have undergone LVAD implantation have been supported by pulsatile devices. Unfortunately, the use of the latter devices is associated with significant comorbidity, primarily as a result of their large size and limited durability. The HeartMate II and the Jarvik 2000 pumps, both of which incorporate axial-flow and rotary pump technology represent the next generation of devices. The clinical use of these newer axial-flow pumps have resulted in superior outcomes, including significantly reduced complication rates with improved durability. However, as with all new technology, axial-flow LVADs have also introduced a ...

Two recent studies in the Journal of the American College of Cardiology (JACC) look at findings from the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) Study. New data from MADIT-CRT study identifies who are the super-responders, and a second paper finds a possible new effect of statins. The first study looked at predictors of left ventricular ejection fraction (LVEF) super-response to cardiac resynchronization therapy with defibrillator (CRT-D) and whether super-response translated into improved, event-free survival in patients with mildly symptomatic heart failure (HF). Currently, few data exist on predictors of super-response to CRT-D and associated morbidity and mortality in mildly symptomatic HF populations. Based on the findings from the study, researchers concluded that six baseline factors predict LVEF super-response in CRT-D-treated patients with mild HF. These factors are: female sex, no prior myocardial infarction, QRS ...

The hypothesis of this study is that patients with dilated nonischemic cardiomyopathy who require support with an implanted left ventricular assist device (LVAD) for chronic refractory heart failure can, with a specific two-staged medical regimen designed to enhance maximal reverse remodeling (an angiotensin converting enzyme inhibitor, beta blocker, angiotensin receptor blocker, aldosterone antagonist and digoxin [stage 1]) and prevent/reverse myocardial atrophy (the β2 agonist clenbuterol [stage 2]), recover adequate left ventricular systolic function to allow LVAD explantation and subsequent intermediate-term survival without need for mechanical circulatory support or heart transplantation.. Within one year of this studys start, a new LVAD became the standard of care for implantation, so the study device became an inferior standard of care shortly thereafter. By 2012 the trial was stopped for futility in enrollment. Thus, certain original outcomes have been deleted, specifically because ...

APPROVAL FOR A MODIFICATION TO THE INDICATIONS FOR USE FOR THE COGNIS CRT-D MODELS N118, N119; LIVIANCRT-D MODELS H220, H225, H227 AND H229; AND CONTAK RENEWAL 3 RF HE CRT-D MODELSH210, H215, H217, H219 CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATORS (CRT-DS) AS FOLLOWS:THESE BOSTON SCIENTIFIC CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATORS (CRT-DS) ARE INDICATED FOR PATIENTS WITH HEART FAILURE WHO RECEIVE STABLE OPTIMAL PHARMACOLOGIC THERAPY (OPT) FOR HEART FAILURE AND WHO MEET ANY ONE OF THE FOLLOWING CLASSIFICATIONS:1) MODERATE TO SEVERE HEART FAILURE (NYHA CLASS III-IV) WITH EF = 120 MS; OR2) LEFT BUNDLE BRANCH BLOCK (LBBB) WITH QRS >= 130 MS, EF

Heart failure represents a primary cause of morbidity and mortality in older people and despite significant therapeutic advances, it is still characterized by important unmet needs, thus remaining a challenging field of clinical research. The recent PARADIGM-HF trial compared the novel compound LCZ696, a combination of the angiotensin receptor blocker valsartan and the neprilysin inhibitor sacubitril, versus the angiotensin-converting enzyme inhibitor enalapril in 8,442 patients with symptomatic chronic systolic heart failure. LCZ696 led to a 20% reduction in the rate of death or hospitalization for heart failure and a 16% reduction in the rate of all-cause death compared to enalapril at 3.5 years of follow-up. Despite those impressive results, the clinical application of this novel agent that requires the substitution of a cornerstone of current heart failure therapy, the angiotensin-converting enzyme inhibitors, should follow careful steps as imposed by the study design, the recruited population and

Miami - Dental Implant Failure Treatment While a dental implant is essentially an artificial tooth root that is meant to last a lifetime, failure does happ

BACKGROUND: Congestion is a primary driver of symptoms in patients with acute heart failure, and relief of congestion is a critical goal of therapy. Monitoring of response to therapy through the assessment of daily weights and net fluid loss is the current standard of care, yet the relationship between commonly used markers of decongestion and both patient reported symptom relief and clinical outcomes are unknown.. METHODS AND RESULTS: We performed a retrospective analysis of the randomized clinical trial, diuretic optimization strategy evaluation in acute heart failure (DOSE-AHF), enrolling patients hospitalized with a diagnosis of acute decompensated heart failure. We assessed the relationship among 3 markers of decongestion at 72 hours-weight loss, net fluid loss, and percent reduction in serum N terminal B-type natriuretic peptide (NT-proBNP) level-and relief of symptoms as defined by the dyspnea visual analog scale area under the curve. We also determined the relationship between each ...

Recent advances in the treatment of systolic congestive heart failure are based on the results of randomized, double-blind, placebo-controlled, multicenter trials. Heart failure is a complex condition, and its treatment requires consideration of two separate goals: symptom relief and tertiary prevention.. The goal of tertiary prevention may be achieved by altering the natural history of the progressive left ventricular remodeling process that leads to further increase in the size of the left ventricle, along with a decline in the ejection fraction. Remodeling is associated with a poor prognosis: it causes further deterioration of congestive heart failure along with a vicious circle of further remodeling.. Initially, heart failure was approached as a problem of excessive salt and water retention (cardiorenal model). Later, it was considered to be a problem caused by abnormalities in the pumping capacity of the heart, combined with excessive peripheral vasoconstriction (cardiocirculatory ...

IVF Failure Treatment in Himachal Pradesh, Multiple IVF Failure Treatment in Himachal Pradesh, Fail in First IVF Cycle Treatment in Himachal Pradesh, Call +91-9654403309

TY - JOUR. T1 - Risk factors for hospital readmission of patients with heart failure. T2 - A cohort study. AU - Sadeq, Adel. AU - Sadeq, Ahmed. AU - Sadeq, Asil. AU - Alkhidir, Israa. AU - Aburuz, Salahedin. AU - Mellal, Abdullah. AU - Al Najjar, Munther. AU - Elnour, Asim. PY - 2020/7/1. Y1 - 2020/7/1. N2 - Aim: The aim of this study was to develop a risk factor model for hospital readmission in patients with heart failure. Background: Identification of risk factors and predictors of readmission to hospital in patients with heart failure is very crucial for improved clinical outcomes. Objective: The objective of the current study was to investigate and delineate the risk factors that may be implicated in putting a patient at greater risk of readmission due to uncontrolled heart failure. Materials and Methods: This is a prospective follow-up cohort study of 170 patients with heart failure at a tertiary hospital in Al Ain city in the United Arab Emirates. We have developed a risk factor model ...

Approximately two-thirds of patients implanted with ventricular assist devices recover sufficiently to requalify for heart transplantation, and the other one-third die of complications that are often secondary to delayed ventricular assist device implantation and subsequent end-organ failure. To determine whether any preoperative predictors of survival exist, univariate statistics and multivariate stepwise logistic regression analysis were performed on pre-ventricular assist device demographics, hemodynamics, and blood chemistry in 186 patients receiving Thoratec ventricular assist devices (Thoratec Laboratories Corp., Berkeley, Calif.) while awaiting transplantation. The duration of circulatory support averaged 19.6 days (maximum, 226 days). One hundred thirty-seven patients (74%) received biventricular support, 47 received isolated left ventricular assist devices, and two received right ventricular assist devices. The average blood flow was 5.0 +/- 0.9 L/min. One hundred eighteen patients (63%)

TY - JOUR. T1 - Prognostic effect and modulation of cardiac sympathetic function in heart failure patients treated with cardiac resynchronization therapy. AU - Moreira, Rita Ilhão. AU - Abreu, Ana. AU - Portugal, Guilherme. AU - Oliveira, Luís. AU - Oliveira, Mário. AU - Rodrigues, Inês. AU - Cruz, Madalena Coutinho. AU - Cunha, Pedro Silva. AU - Santos, Vanessa. AU - Clara, Helena Santa. AU - Carmo, Miguel Mota. AU - Ferreira, Rui Cruz. PY - 2020/2. Y1 - 2020/2. N2 - Background: Cardiac autonomic dysfunction as assessed by 123 I-metaiodobenzylguanidine ( 123 I-mIBG) scintigraphy is associated with poor prognosis in heart failure (HF) patients. Although cardiac resynchronization therapy (CRT) has emerged as an effective therapy in improving outcomes on HF patients, its effect on cardiac sympathetic nervous function is still not fully understood. We aimed to study the value of pre-implantation 123 I-mIBG late heart-to-mediastinum ratio (HMR) as a predictor of response and outcomes after CRT ...

TY - JOUR. T1 - Eosinophilic heart disease with vasculitis. T2 - Supported by HeartMate left ventricular assist device and heart transplantation. AU - Hsu, Chiao Po. AU - Chang, Shiao Hwang. AU - Wang, Jih Shiuan. AU - Shih, Chun Che. AU - Lai, Shiau Ting. AU - Yang, An Hang. PY - 2002/4/15. Y1 - 2002/4/15. N2 - Eosinophilic heart disease is rarely seen in clinical practice. We report a patient with eosinophilic heart disease who presented with acute myocardial infarction and congestive heart failure. Because of lack of a donor organ and progressive deterioration of his general condition in spite of intraaortic balloon pumping, a left ventricular assist device (HeartMate 1000 IP; Thermo Cardiosystems Inc, Woburn, MA) was implanted before development of irreversible multiple organ failure and was followed by heart transplantation.. AB - Eosinophilic heart disease is rarely seen in clinical practice. We report a patient with eosinophilic heart disease who presented with acute myocardial infarction ...

Fortis has set up a world-class comprehensive centre for heart failure and heart transplant, at the Fortis Malar Hospital, in Chennai, India. The speciality centre under the leadership of K R Balakrishnan, director Cardiac Sciences and Suresh Rao K G, chief of Cardiac Anaesthesia and Critical Care, is ably supported by an experienced team of leading cardiac experts. It offers Indias first comprehensive Heart Failure, Heart Transplant and Artificial Heart Programme with extensive options for treatment and management of congestive heart failure.. Inaugurating the centre, Aditya Vij, chief executive officer, Fortis Healthcare Limited and chairman, Fortis Malar Hospitals Limited said, Advances in medicine have made heart transplants safer and a real option in managing cases of end stage heart failure. Cardiac care at Fortis Malar is well established and ranked amongst the finest in the country. Our team of highly accomplished doctors led by Balakrishnan and Rao have done pioneering work in the ...

Definition of high-output heart failure in the Legal Dictionary - by Free online English dictionary and encyclopedia. What is high-output heart failure? Meaning of high-output heart failure as a legal term. What does high-output heart failure mean in law?

The global cardiac resynchronization therapy (CRT) market is expected to reach USD 9.2 billion by 2025, according to a new report by Grand View Research, Inc. Increasing prevalence of cardiac disorders and rising incidences of heart failure are expected to boost the CRT market growth over the forecast period.. According to statistics published by the Sudden Cardiac Arrest Foundation in 2016, about 6.0 million people within the U.S. region suffer from cardiac disorders, of which 0.8 million are affected by atrioventricular block leading to cardiac failure. Such a huge number leads to an increased cost of about USD 20.0-56.0 billion annually. CRT devices are being predominantly used to prevent the surgical cost and readmission rate in hospitals, thereby propelling its growth.. In addition, the on-going research to develop smaller, wireless/leadless and long-lasting CRT devices is expected to be a vital impact rendering driver. For instance, in September 2016, EBR Systems Inc., announced that it ...

TY - JOUR. T1 - Frequency and Significance of Acute Heart Failure Following Liver Transplantation. AU - Eimer, Micah J.. AU - Wright, Jennifer M.. AU - Wang, Edward C.. AU - Kulik, Laura. AU - Blei, Andres. AU - Flamm, Steven. AU - Beahan, Maribeth. AU - Bonow, Robert O.. AU - Abecassis, Michael. AU - Gheorghiade, Mihai. N1 - Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2008/1/15. Y1 - 2008/1/15. N2 - Reversible cardiomyopathy has been reported in patients after liver transplantation. However, there are few data on the incidence, risk factors, and prognosis of this condition. Liver transplantation recipients who underwent preoperative right- and left-sided cardiac catheterization as well as preoperative transthoracic echocardiography from 2001 to 2005 were identified. Eighty-six patients met the outlined criteria and were included in the study. The incidence of severe heart failure (HF) after transplantation in this population was 6 of 86 (approximately 7%). Patients who ...

Our study demonstrated an increase in LV relaxation during diastole (inferred from the absolute increase in IVPG) with exercise in both normal subjects and in patients with heart failure. However, this mechanism was significantly impaired in the heart failure group compared with normal subjects. We provided evidence for a strong relationship between the ability to augment the diastolic LV relaxation (represented by the delta IVPG) with exercise and the V̇o2 max. Our study also demonstrated that in patients with heart failure, the decreased ability to augment the diastolic relaxation is responsible for the inability to accommodate the increase in estimated preload during exercise, resulting in higher filling pressures.. Regional diastolic pressure differences have been identified in the left ventricle only recently and their importance in determining diastolic function now becomes evident. Ling and colleagues (25) described the suction effect that develops secondary to a pressure drop between ...

OBJECTIVES--To determine the effects of captopril and oxygen on sleep quality in patients with mild to moderate cardiac failure. DESIGN--An open observational study. PATIENTS--12 patients with New York Heart Association class II-III heart failure were studied at baseline. 9 of these patients were then examined at the end of 1 month of treatment with captopril; 9 of the patients were separately assessed during a single night of supplementary oxygen. MAIN OUTCOME MEASURES--Sleep patterns by polysomnography, overnight oximetry, and subjective sleep assessment using visual analogue scores. RESULTS--Abnormal sleep was present in all baseline studies. Complete polysomnograms after treatment with captopril were obtained in 8 patients. Light sleep (stages 1 and 2) was reduced (mean (SEM) 61%(8)% to 48%(6)% actual sleep time, P , 0.05) but slow wave (stages 3 and 4) and REM (rapid eye movement) sleep increased (25%(6)% to 31%(5)%, 14%(2)% to 21%(5)% actual sleep time, P , 0.05). Apnoeic episodes (242(59) ...

December 17, 2012 - BioControl Medical has announced that the pilot clinical study of its CardioFit vagus nerve stimulation system has been recognized as seminal original research in the European Journal of Heart Failure. According to a recent editorial, the highly cited open-label phase II study [of the CardioFit] by De Ferrari et al. demonstrated for the first time that chronic vagus nerve stimulation is associated with improvements in New York Heart Association (NYHA) class, six minute walk test, left ventricular ejection fraction, and systolic volumes up to one year, setting the stage for further investigations and clinical trials in this new era of device thearapy.[1,2]. Conducted in Italy, Germany, The Netherlands and Serbia, the multi-center pilot clinical study of the CardioFit was designed to assess the six-month safety and clinical response to the therapy in 32 patients with NYHA II-IV heart failure on optimized background medical therapy. Study data showed that patients experienced ...

FRISCO, TX - July 18, 2017) Baylor Scott & White Medical Center - Centennial has received the Get With The Guidelines®-Heart Failure Gold Plus Quality Achievement Award for implementing specific quality improvement measures and secondary prevention guidelines outlined by the American Heart Association/American College of Cardiology Foundation guidelines for patients with heart failure.. Get With The Guidelines-Heart Failure is a quality improvement program that helps hospital teams follow the most up-to-date, research-based standards with the goal of speeding recovery and reducing hospital readmissions for heart failure patients.. Launched in 2005, numerous published studies have demonstrated the programs success in achieving patient outcome improvements, including reductions in 30-day readmissions.. Baylor Scott & White - Centennial is dedicated to improving the quality of care for our heart failure patients, said Jay Krishnaswamy, chief executive officer of Baylor Scott & White - ...

Mechanical circulatory support devices, such as ventricular assist devices and temporary total artificial hearts, can be surgically implanted in people with advanced heart failure to help the hearts pumping function.. But people with advanced heart failure often also suffer from multi-organ dysfunction syndrome, which can lead to death after a device is implanted and is associated with atypical white blood cell activity. When patients and doctors are considering a mechanical assist device, current clinical methods used to predict treatment results have limitations: They do not perform well in very sick patients and they do not use molecular information. That lack of precision in predicting treatment outcomes can complicate the shared decision-making process between patients and their doctors.. Dr. Mario Deng, the studys principal investigator, was also a co-developer of an FDA-approved molecular blood test called AlloMap, which is used to diagnose organ rejection in heart transplant ...

Mann DL. Management of patients with heart failure with reduced ejection fraction. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, eds. Braunwalds Heart Disease: A Textbook of Cardiovascular Medicine. 11th ed. Philadelphia, PA: Elsevier Saunders; 2019:chap 25.. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/ AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Cardiac Failure. 2017;23(8):628-651. PMID: 28461259 www.ncbi.nlm.nih.gov/pubmed/28461259.. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240-e327. PMID: 23741058 www.ncbi.nlm.nih.gov/pubmed/23741058.. BACK TO TOP. Review ...

Looking for online definition of cardiac cachexia in the Medical Dictionary? cardiac cachexia explanation free. What is cardiac cachexia? Meaning of cardiac cachexia medical term. What does cardiac cachexia mean?

Part B.3 requires medical reasons related to chronic heart failure that caused you to be unable to achieve a workload equivalent to 5 METs or less (exertion approximately equal to brisk walking) during an exercise tolerance test.. Part B.3.a can be satisfied by inability to perform 5 METs exertion on an exercise test due to symptoms of heart failure, thus precluding the ability to do even sedentary work. Symptoms that indicate worsening heart failure developing during exercise are severe shortness of breath (SOB) and weakness, as well as chest discomfort such as angina pectoris and subjectively forceful heart beats (palpitations). Objective findings suggesting the onset of failure during exercise are the development of an S3 heart sound (an abnormal heart sound heard with a stethoscope that indicates ventricular dysfunction) or even frank pulmonary edema (fluid in the lungs). The pulmonary edema can be heard with a stethoscope as wet-sounding rales with inspiration, especially at the bottoms ...

TY - JOUR. T1 - Meta-analysis of Risk of Ventricular Arrhythmias After Improvement in Left Ventricular Ejection Fraction During Follow-Up in Patients With Primary Prevention Implantable Cardioverter Defibrillators. AU - Smer, Aiman. AU - Saurav, Alok. AU - Azzouz, Muhammad Soubhi. AU - Salih, Mohsin. AU - Ayan, Mohamed. AU - Abuzaid, Ahmed. AU - Akinapelli, Abhilash. AU - Kanmanthareddy, Arun. AU - Rosenfeld, Lynda E.. AU - Merchant, Faisal M.. AU - Abuissa, Hussam. PY - 2017/7/15. Y1 - 2017/7/15. N2 - Implantable cardioverter defibrillators (ICDs) reduce the risk of sudden cardiac death in patients with impaired left ventricular ejection fraction (LVEF). However, there are limited data on the long-term benefit of ICD therapy in patients whose LVEF subsequently improves. We conducted a meta-analysis to evaluate the effect of LVEF improvement on ICD therapy during follow-up. Incidence rate ratios (IRRs) with 95% confidence intervals (CIs) were calculated using random-effects modeling. Sixteen ...

TY - JOUR. T1 - Prediction of right ventricular failure after ventricular assist device implant. T2 - systematic review and meta-analysis of observational studies. AU - Bellavia, Diego. AU - Iacovoni, Attilio. AU - Scardulla, Cesare. AU - Moja, Lorenzo. AU - Pilato, Michele. AU - Kushwaha, Sudhir S. AU - Senni, Michele. AU - Clemenza, Francesco. AU - Agnese, Valentina. AU - Falletta, Calogero. AU - Romano, Giuseppe. AU - Maalouf, Joseph. AU - Dandel, Michael. N1 - © 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.. PY - 2017/7. Y1 - 2017/7. N2 - Right ventricular failure (RVF) after left ventricular assist device (LVAD) implantation is associated with increased morbidity and mortality, but the identification of LVAD candidates at risk for RVF remains challenging. We undertook a systematic review and meta-analysis of observational studies of risk factors associated with RVF after LVAD implant. Thirty-six studies published between 1 January 1995 and 30 ...

While diastolic heart failure refers to the clinical syndrome of heart failure in the setting of a normal ejection fraction. Diagnosis, prognosis. Diastolic dysfunction. Quence of diastolic dysfunction. Heart diastolic dysfunction diastolic heart failure, a major cause of morbidity and mortality, is defined as symptoms of heart failure in a patient with preserved left ventricular function. Recommendations for the Evaluation of Left Ventricular. Patients with diastolic heart failure, as well as those with diastolic dysfunction and little or no congestion, exhibit exercise intolerance for two principal reasons. New concepts in diastolic dysfunction and diastolic heart failure. Diastolic Function by Echocardiography. ...

TY - JOUR. T1 - Association of low body temperature and poor outcomes in patients admitted with worsening heart failure. T2 - A substudy of the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trial. AU - Payvar, Saeed. AU - Spertus, John A.. AU - Miller, Alan B.. AU - Ward Casscells, S.. AU - Pang, Peter S.. AU - Zannad, Faiez. AU - Swedberg, Karl. AU - Maggioni, Aldo P.. AU - Reid, Kimberly J.. AU - Gheorghiade, Mihai. PY - 2013. Y1 - 2013. N2 - Aims Risk stratification in patients admitted with worsening heart failure (HF) is essential for tailoring therapy and counselling. Risk models are available but rarely used, in part because many require laboratory and imaging results that are not routinely available. Body temperature is associated with prognosis in other illnesses, andwe hypothesized that low body temperature would be associated with worse outcomes in patients admitted with worsening HF. Methods and results The Efficacy of Vasopressin ...

The use of electronic discharge orders aimed at providing evidence-based decision support and clear instructions to heart failure patients helped increase compliance with quality care measures and lowered hospital readmission rates, according to research presented at the American College of Cardiologys 62nd Annual Scientific Session.. Despite more widespread use of standardized discharge orders and evidence suggesting their effectiveness, little is known about how they impact adherence to quality measures or hospital readmission rates among heart failure patients. This study showed use of a computerized discharge system was associated with a 23 percent lower all-cause hospital readmission rate and a 10-fold increase in compliance with quality care measures.. Researchers conducted a retrospective study of heart failure patients discharged from 11 hospitals across Utah between January 2011 and September 2012 to determine whether the use of an electronic discharge orders tool was associated with ...